This session will address premarketing risk assessment, mathematics of drug safety, and a brief introduction to benefit-risk (to be discussed further in Session 20).

Have an account?

Pragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum

Session 12: Risk Assessment in Clinical Trials

Session Chair(s)

JP Clement, MD

Be informed and stay engaged.